195 related articles for article (PubMed ID: 32467965)
21. Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept.
Pistollato F; de Gyves EM; Carpi D; Bopp SK; Nunes C; Worth A; Bal-Price A
Environ Health; 2020 Feb; 19(1):23. PubMed ID: 32093744
[TBL] [Abstract][Full Text] [Related]
22. Capturing a Comprehensive Picture of Biological Events From Adverse Outcome Pathways in the Drug Exposome.
Wu Q; Bagdad Y; Taboureau O; Audouze K
Front Public Health; 2021; 9():763962. PubMed ID: 34976924
[No Abstract] [Full Text] [Related]
23. Editorial trend: adverse outcome pathway (AOP) and computational strategy - towards new perspectives in ecotoxicology.
Baudiffier D; Audouze K; Armant O; Frelon S; Charles S; Beaudouin R; Cosio C; Payrastre L; Siaussat D; Burgeot T; Mauffret A; Degli Esposti D; Mougin C; Delaunay D; Coumoul X
Environ Sci Pollut Res Int; 2024 Jan; 31(5):6587-6596. PubMed ID: 37966636
[TBL] [Abstract][Full Text] [Related]
24. Deploying elements of scoping review methods for adverse outcome pathway development: a space travel case example.
Kozbenko T; Adam N; Lai V; Sandhu S; Kuan J; Flores D; Appleby M; Parker H; Hocking R; Tsaioun K; Yauk C; Wilkins R; Chauhan V
Int J Radiat Biol; 2022; 98(12):1777-1788. PubMed ID: 35939057
[TBL] [Abstract][Full Text] [Related]
25. Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia.
; Ockleford C; Adriaanse P; Berny P; Brock T; Duquesne S; Grilli S; Hernandez-Jerez AF; Bennekou SH; Klein M; Kuhl T; Laskowski R; Machera K; Pelkonen O; Pieper S; Smith R; Stemmer M; Sundh I; Teodorovic I; Tiktak A; Topping CJ; Wolterink G; Angeli K; Fritsche E; Hernandez-Jerez AF; Leist M; Mantovani A; Menendez P; Pelkonen O; Price A; Viviani B; Chiusolo A; Ruffo F; Terron A; Bennekou SH
EFSA J; 2017 Mar; 15(3):e04691. PubMed ID: 32625422
[TBL] [Abstract][Full Text] [Related]
26. The 2021 update of the EPA's adverse outcome pathway database.
Mortensen HM; Senn J; Levey T; Langley P; Williams AJ
Sci Data; 2021 Jul; 8(1):169. PubMed ID: 34253739
[TBL] [Abstract][Full Text] [Related]
27. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
[TBL] [Abstract][Full Text] [Related]
28. Expert consultation is vital for adverse outcome pathway development: a case example of cardiovascular effects of ionizing radiation.
Chauhan V; Hamada N; Monceau V; Ebrahimian T; Adam N; Wilkins RC; Sebastian S; Patel ZS; Huff JL; Simonetto C; Iwasaki T; Kaiser JC; Salomaa S; Moertl S; Azimzadeh O
Int J Radiat Biol; 2021; 97(11):1516-1525. PubMed ID: 34402738
[TBL] [Abstract][Full Text] [Related]
29. Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity.
Bal-Price A; Meek MEB
Pharmacol Ther; 2017 Nov; 179():84-95. PubMed ID: 28529068
[TBL] [Abstract][Full Text] [Related]
30. Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome.
; Hernandez-Jerez AF; Adriaanse P; Aldrich A; Berny P; Coja T; Duquesne S; Focks A; Millet M; Pelkonen O; Pieper S; Tiktak A; Topping CJ; Widenfalk A; Wilks M; Wolterink G; Angeli K; Recordati C; Van Durseen M; Aiassa E; Lanzoni A; Lostia A; Martino L; Guajardo IPM; Panzarea M; Terron A; Marinovich M
EFSA J; 2023 Feb; 21(2):e07744. PubMed ID: 36818642
[TBL] [Abstract][Full Text] [Related]
31. An adverse outcome pathway-based approach to assess steatotic mixture effects of hepatotoxic pesticides in vitro.
Lichtenstein D; Luckert C; Alarcan J; de Sousa G; Gioutlakis M; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg A; Rahmani R; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla SJ; Wollscheid B; Zucchini-Pascal N; Braeuning A; Lampen A
Food Chem Toxicol; 2020 May; 139():111283. PubMed ID: 32201337
[TBL] [Abstract][Full Text] [Related]
32. Putative adverse outcome pathways of the male reproductive toxicity derived from toxicological studies of perfluoroalkyl acids.
Lu T; Mortimer M; Li F; Li Z; Chen L; Li M; Guo LH
Sci Total Environ; 2023 May; 873():162439. PubMed ID: 36848992
[TBL] [Abstract][Full Text] [Related]
33. An adverse outcome pathway-based approach to assess the neurotoxicity by combined exposure to current-use pesticides.
Hirano T; Ikenaka Y; Nomiyama K; Honda M; Suzuki N; Hoshi N; Tabuchi Y
Toxicology; 2023 Dec; 500():153687. PubMed ID: 38040083
[TBL] [Abstract][Full Text] [Related]
34. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?
Marty S; Beekhuijzen M; Charlton A; Hallmark N; Hannas BR; Jacobi S; Melching-Kollmuss S; Sauer UG; Sheets LP; Strauss V; Urbisch D; Botham PA; van Ravenzwaay B
Crit Rev Toxicol; 2021 Apr; 51(4):328-358. PubMed ID: 34074207
[TBL] [Abstract][Full Text] [Related]
35. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
[TBL] [Abstract][Full Text] [Related]
36. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.
Svingen T; Villeneuve DL; Knapen D; Panagiotou EM; Draskau MK; Damdimopoulou P; O'Brien JM
Toxicol Sci; 2021 Nov; 184(2):183-190. PubMed ID: 34534351
[TBL] [Abstract][Full Text] [Related]
37. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
[TBL] [Abstract][Full Text] [Related]
38. Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429).
Tsamou M; Roggen EL
J Alzheimers Dis Rep; 2022; 6(1):271-296. PubMed ID: 35891639
[TBL] [Abstract][Full Text] [Related]
39. Providing Adverse Outcome Pathways from the AOP-Wiki in a Semantic Web Format to Increase Usability and Accessibility of the Content.
Martens M; Evelo CT; Willighagen EL
Appl In Vitro Toxicol; 2022 Mar; 8(1):2-13. PubMed ID: 35388368
[TBL] [Abstract][Full Text] [Related]
40. The potential of AOP networks for reproductive and developmental toxicity assay development.
Knapen D; Vergauwen L; Villeneuve DL; Ankley GT
Reprod Toxicol; 2015 Aug; 56():52-5. PubMed ID: 25889759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
